- Home
- HDRN vs CRBP Comparison
HDRN vs CRBP Comparison
Compare HDRN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HDRN | CRBP |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.8M | 184.4M |
| IPO Year | 2024 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HDRN | CRBP |
|---|---|---|
| Price | $1.88 | $9.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 73.1K | ★ 471.7K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.71 | $7.12 |
| 52 Week High | $2.63 | $20.56 |
Technical Indicators
Market Signals| Indicator | HDRN | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 31.15 | 59.77 |
| Support Level | $1.71 | $7.42 |
| Resistance Level | $2.34 | $10.74 |
| Average True Range (ATR) | 0.25 | 0.48 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 18.57 | 84.41 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.